高翠红,孙文杰,崔娇姣
GAO Cuihong,SUN Wenjie,CUI Jiaojiao

• 1:唐山市妇幼保健院

摘要(Abstract)：

目的:探讨白细胞介素6(IL-6)、白细胞介素8(IL-8)和基质金属蛋白酶2(MMP-2)、MMP-9在浆液性卵巢癌(OSAC)患者血清及腹腔积液中的表达水平及相关性,并分析其与OSAC预后的关系。方法:选择经术后病理确诊为OSAC的56例患者为研究对象(OSAC组),同期因盆腔包块待查术后证实为卵巢良性肿瘤患者32例为对照组(良性肿瘤组),采用酶联免疫吸附法(ELISA)分别测定两组患者的血清及腹腔积液中IL-6、IL-8、MMP-2和MMP-9的水平;并采用Spearman等级相关分析以上指标在OSAC组血清与腹腔积液中的关系。结果:IL-6、IL-8、MMP-2和MMP-9在OSAC组患者的血清和腹腔积液中的表达高于良性肿瘤组(P <0.05); OSAC组Ⅲ、Ⅳ期患者腹腔积液中的IL-6、IL-8、MMP-2和MMP-9水平均高于Ⅰ、Ⅱ期患者,高、中分化组患者各指标水平低于低分化组,差异有统计学意义(P <0.05); IL-6、MMP-2和MMP-9在OSAC组血清和腹腔积液中的表达呈正相关(t=0.401,t=0.465,t=0.290,P <0.05)。结论:腹腔积液中IL-6、IL-8、MMP-2和MMP-9水平可用于鉴别卵巢良恶性病变,且与OSAC预后有关。
Objective: To investigate the expression level of interleukin-6( IL-6),interleukin-8( IL-8),matrix metalloproteinase 2( MMP-2) and matrix metalloproteinase-9( MMP-9) in serum and peritoneal effusion of patients with ovarian serous adenocarcinoma( OSAC),and to analyze their relationship with OSAC prognosis. Methods: Fifty-six OSAC patients confirmed by postoperative pathology were selected as the research object( OSAC group),and 32 patients with ovarian benign tumor confirmed after operation due to pelvic mass were selected as control group( benign tumor group). The levels of IL-6,IL-8,MMP-2 and MMP-9 in serum and peritoneal effusion of the two groups were measured by enzyme-linked immunosorbent assay( ELISA),and Spearman was used to detect the levels of IL-6,IL-8,MMP-2 and MMP-9 in serum and ascites of the two groups Grade correlation analysis was used to analyze the relationship between serum and ascites in OSAC group.Results: The expression of IL-6,IL-8,MMP-2 and MMP-9 in serum and peritoneal effusion of OSAC group was higher than that of benign tumor group( P < 0. 05); the levels of IL-6,IL-8,MMP-2 and MMP-9 in ascites of patients with stage III and IV in OSAC group were higher than those in stage I and II,while the levels of each index in high and medium differentiation group were lower than those in low differentiation group( P < 0. 05); the expressions of IL-6,MMP-2 and MMP-9 in serum and ascites of OSAC group were positively correlated( t = 0. 401,t = 0. 465,t = 0. 290,P < 0. 05). Conclusions:The levels of IL-6,IL-8,MMP-2 and MMP-9 in peritoneal effusion can be used to differentiate benign and malignant ovarian lesions,and are related to the OSAC prognosis.

关键词(KeyWords)： 白细胞介素6;白细胞介素8;基质金属蛋白酶2;基质金属蛋白酶9;浆液性卵巢癌;腹腔积液
interleukin-6(IL-6);interleukin-8(IL-8);matrix metalloproteinase 2(MMPs-2);matrix metalloproteinase 9(MMPs-9);ovarian serous adenocarcinoma(OSAC);peritoneal effusion

Abstract:

Keywords:

基金项目(Foundation): 河北省2019年医学科学研究计划(20191531)

作者(Author): 高翠红,孙文杰,崔娇姣
GAO Cuihong,SUN Wenjie,CUI Jiaojiao

DOI: 10.19367/j.cnki.2096-8388.2020.08.022

参考文献(References)：

• [1]孙艳丽，李家斌．不明原因腹水患者266例病因及临床特点分析[J]．中国社区医师，2017,33(30):69-72．
• [2]YANG Y,ZHAO X,LI X,et al.Effects of anti-CD44monoclonal antibody IM7 carried with chitosan polylactic acid-coated nano-particles on the treatment of ovarian cancer[J].Oncol Lett,2017,13(1):99-104．
• [3]PAPA A,CARUSO D,STRUDEL M,et al.Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment[J].J Transl Med.2016,14(267):1-18．
• [4]KRYCZEK I,GRYBOS M,KARABON L,et al.IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity.Br J Cancer,2000,82(3):621-628．
• [5]IVARSSON K,EKERYDH A,FYHR IM,et al.Upregulation of interleukin-8 and polarizede pithelial expression of interleukin-8 receptorain ovarian carcinomas[J].Acta Obstet Gynecol Scand,2000,79(9):777-784．
• [6]关慧，王瑄，关瑞，等．白蛋白结合型紫杉醇与紫杉醇治疗老年晚期卵巢癌疗效与安全性比较[J]．实用老年医学，2016,30(5):415-417．
• [7]DAVIDSON B,STAVNES HT,HELLESYLT E,et al.MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells inserous effusions[J].Hum Pathol,2016,47 (1):104-108．
• [8]KIM S,KIM B,SONG Y.Ascites modulates cancer cell behavior,contributing to tumor heterogeneity in ovarian cancer[J].Cancer Sci,2016,107(9):1173-1178．
• [9]TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statisitics[J].CA Cancer J Clin,2015,65(2):87-108．
• [10]SZENDER J B,EMMONS T,et al.Impact of ascites volume on clinical outcomes in ovarian cancer:a cohort study[J].Gynecol Oncol,2017,146(3):491-497．
• [11]毛柳．卵巢癌腹水及外周血CD4+CD25+Treg/CD4+T细胞含量及其意义分析[J]．中国妇幼保健，2016,31(22):4871-4874．
• [12]NIK N N,VANG R,SHIHLE M,et al.Origin and pathogenesis of pelvic(ovarian,tubal,and primary peritoneal) serous carcinoma[J].Annu Rev Pathol,2014,9 (1):27-45．
• [13]刘小丽，杨志明，王黎黎，等．卵巢癌细胞转移与组织、外周血中T淋巴细胞亚群失衡的相关性分析[J]．中国医师进修杂志，2017,40 (5):390-394．
• [14]WATANABE H,IWASE M,OHASHI M,et al.Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines[J].Oral Oncol,2002,38(7):670-679．
• [15]瓮占平，王金会，纪向虹，等．基质金属蛋白酶抑制剂RECK基因在卵巢癌细胞株中的表达及意义[J]．中国优生与遗传杂志，2015,23 (3):14-26．
• [16]FATHY M,Al ANSARY M,ZAKARIA M,et al.Role of vascular endothelial growth factor (VEGF) in diagnosis of pleural effusion of different or-igins[J].Egypt J Chest Dis Tubercu,2014,63(4):611-615．
• [17]张艳慧，冯艳奇，张爱萍．卵巢癌组织中ERCC1、MMP-2、VEGF表达变化及意义[J]．山东医药，2017,57(10):67-69．
• [18]张永波，胡远强．VEGF和MMP-2在卵巢乳头状癌组织中表达特征及临床意义[J]．现代仪器与医疗，2016,22(6):111-113．
• [19]ZHANG Y,CHEN Q.Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer[J].Braz J Med Biol Res,2017,50(6):e6104．
• [20]苏亚娟，王淑敏，王金凤，等．VEGF、MMP-2在卵巢癌患者血清及腹水中的表达[J]．中国实验诊断学，2008,12(2):242-244.

文章评论(Comment)：